Maritech Fucoidan Extracts Get FDA GRAS
Maritech fucoidan ingredients are the first and only high-purity fucoidan extracts to achieve GRAS status, says the company.
Photo © iStockphoto.com/BryanToro
A biotechnology company called Marinova Pty. Ltd. (Tasmania, Australia) announced that its proprietary fucoidan extract is now Generally Recognized as Safe (GRAS) by FDA. Maritech fucoidan ingredients are the first and only high-purity fucoidan extracts to achieve GRAS status, says the company.
The FDA responded “no questions” to findings by an independent panel of experts. The panel determined that the fucoidan extracts from two species of seaweed-Undaria pinnatifida and Fucus vesiculosus-are safe for use as a food ingredient in dosages of up to 250 mg per day. Fucoidan is a bioactive polysaccharide that occurs naturally in brown seaweed, and the company says that its fucoidan extracts have been shown to support immune and digestive health, possess antiaging properties, and may aid in tumor suppression, anti-inflammation, and viral inhibition.
“GRAS recognition is testament to the safety and quality of Maritech fucoidan extracts, giving our customers even further confidence that they are getting the highest quality and most effective fucoidan ingredients on the market,” said Damien Stringer, PhD, operations manager, Marinova, in a press release.
The company notes that this GRAS status achievement follows previous regulatory accreditations in such markets as Australia, Canada, Europe, and China, among others. The extracts have also been granted non-GMO, Kosher, and Halal certifications.
Also read:
Senate Committee has released the text of 2024 Farm Bill, with changes to hemp regulations
November 19th 2024The U.S. Senate Committee on Agriculture, Nutrition, & Forestry has introduced the Rural Prosperity and Food Security Act, which will serve as the Senate’s draft for the 2024 Farm Bill.
NPA’s lawsuit against FDA on NMN stayed pending agency’s decision on citizen petition
November 6th 2024The court has granted a joint motion for stay filed by NPA and FDA, pending the agency's decision on the citizen petition asking FDA to reverse its stance on NMN's status as a dietary ingredient.
